#neurological biomarkers market share

[businesspointnews]

Neurological Biomarkers Market Size, Demand, Share, Growth and Forecast 2023-2028

IMARC Group has recently released a new research study titled “Neurological Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios. How Big is the Neurological Biomarkers…

[aarunresearcher]

United States neurological biomarkers market size is projected to exhibit a growth rate (CAGR) of 4.20% during 2024-2032. The elevating adoption of minimally invasive procedures and the growing number of clinical trials represent some of the key factors driving the market.

[willyskristina]

Neurodegenerative Disease Market

Neurodegenerative Disease Market Size, Share, Trends: Biogen Inc. Leads

Emerging gene therapies and precision medicine approaches

Market Overview: 

The global Neurodegenerative Disease Market is projected to grow at a CAGR of XX% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031. North America dominates the market, driven by a high prevalence of neurodegenerative disorders, advanced healthcare infrastructure, and significant investments in research and development. Key metrics include rising aging population, increasing awareness about neurological disorders, and growing pipeline of novel therapies.

The Neurodegenerative Disease Market is expanding rapidly, driven by the growing global burden of neurological disorders, advances in diagnostic technology, and an increase in research activities aimed at generating novel treatment options. The market is distinguished by a heavy emphasis on personalised medicine techniques, the development of novel biomarkers for early detection, and the incorporation of digital health technologies into disease management. Pharmaceutical companies are stepping up their efforts to produce disease-modifying medications, notably for illnesses such as Alzheimer's and Parkinson's disease, which currently lack cures.

DOWNLOAD FREE SAMPLE

Market Trends: 

The Neurodegenerative Disease Market is seeing a considerable increase in the discovery and implementation of gene treatments and precision medicine approaches. This transition is being driven by advances in genetic research and the promise of tailored medicines to address the underlying causes of neurodegenerative illnesses. Gene therapies seek to fix or replace defective genes associated with various disorders, with the potential for long-term or even curative benefits. Major pharmaceutical and biotech corporations are making significant investments in gene therapy research for illnesses such as Huntington's disease and spinal muscular atrophy. For example, Novartis' Zolgensma, a gene treatment for spinal muscular atrophy, has demonstrated promise in clinical trials.

Market Segmentation: 

Alzheimer's Disease segment accounts for the greatest market share in the Neurodegenerative Disease Market. This dominance is due to the high frequency of Alzheimer's disease, the most common type of dementia, which affects millions of people worldwide. According to the Alzheimer's Association, more than 6 million Americans are living with Alzheimer's in 2021, with the figure expected to climb to nearly 13 million by 2050.

Market Key Players:

Biogen Inc.

F. Hoffmann-La Roche Ltd.

Novartis AG

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

UCB S.A.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[skyquest-market-research]

MicroRNA Market Key Insights and Growth Opportunities, Forecast - 2031

The global microRNA (miRNA) market has gained substantial attention in recent years, driven by its expanding applications in disease diagnosis, therapeutics, and biomedical research. As per the latest insights from SkyQuest Technology, the global microRNA market is projected to reach a value of USD 3.58 billion by 2031, growing at a CAGR of 12.9% from 2024 to 2031. This growth is fueled by advancements in RNA-based research, rising incidences of chronic diseases, and the increasing adoption of miRNA-based diagnostics and therapeutics.

What is Driving the Growth of the MicroRNA Market?

Advancements in Biotechnology The continuous evolution of next-generation sequencing (NGS) and molecular biology technologies has significantly enhanced the detection, profiling, and understanding of miRNA. This progress has opened doors for new therapeutic and diagnostic applications.

Rising Incidence of Chronic and Genetic Diseases The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to a growing demand for miRNA-based diagnostics and therapeutics, as these molecules hold the potential to modulate gene expression effectively.

Emerging Role in Precision Medicine MicroRNA is becoming a vital component in precision medicine, offering solutions tailored to an individual’s genetic profile. This trend has driven research funding and investment in miRNA technologies.

Growing Focus on Early Diagnosis Early detection of diseases is crucial for effective treatment, and miRNA-based diagnostic tools are gaining popularity for their accuracy, reliability, and ability to identify diseases in their initial stages.

Request a Sample Report - https://www.skyquestt.com/sample-request/microrna-market

Market Segmentation: A Closer Look at Key Areas

By Application

Cancer Diagnostics & Therapeutics: The largest segment due to the rising prevalence of cancer and miRNA’s role in tumor suppression and oncogene regulation.

Neurological Disorders: Increasing use in diagnosing and treating neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Cardiovascular Diseases: miRNA’s ability to regulate gene expression has made it essential in addressing heart diseases.

Others: Includes applications in metabolic disorders, infectious diseases, and stem cell research.

By Technology

Next-Generation Sequencing (NGS): Widely adopted for profiling and discovering novel miRNA biomarkers.

qRT-PCR: A cost-effective and reliable technology for miRNA quantification.

Microarray: Primarily used for miRNA expression profiling.

By End-User

Research Institutes: Significant demand for miRNA in academic and industrial research.

Pharmaceutical and Biotech Companies: Focused on developing miRNA-based drugs and therapies.

Clinical Diagnostics Laboratories: Increasing use of miRNA as diagnostic markers.

Speak to an Analyst for Customization - https://www.skyquestt.com/speak-with-analyst/microrna-market

Regional Insights: The Global Reach of the MicroRNA Market

North America North America dominates the market, driven by robust R&D funding, advanced healthcare infrastructure, and the growing adoption of miRNA technologies in clinical diagnostics and therapeutics.

Europe Europe represents a significant share of the market due to the rising prevalence of chronic diseases, government support for RNA research, and the strong presence of biotechnology companies in countries like Germany and the UK.

Asia-Pacific Asia-Pacific is the fastest-growing region, with countries like China, Japan, and India witnessing increasing investments in biotechnology and a growing focus on personalized medicine.

Latin America & the Middle East These regions are gradually emerging as potential markets, driven by increasing awareness of miRNA-based applications and improving healthcare infrastructure.

Make a Purchase Inquiry - https://www.skyquestt.com/buy-now/microrna-market

Key Market Players in the MicroRNA Landscape

The microRNA market is highly competitive, with numerous companies investing in R&D to develop innovative diagnostics and therapeutics. Major players include:

Thermo Fisher Scientific Inc.

Qiagen N.V.

Merck KGaA

Illumina, Inc.

Horizon Discovery Group plc

GeneCopoeia, Inc.

NanoString Technologies, Inc.

Abcam plc

New England Biolabs

Rosetta Genomics Ltd.

These companies are driving the market through strategic collaborations, partnerships, and the development of novel miRNA-based products.

Emerging Trends in the MicroRNA Market

Integration of Artificial Intelligence (AI) in miRNA Research AI and machine learning are being employed to analyze complex miRNA datasets, accelerating the discovery of novel biomarkers and therapeutic targets.

miRNA-Based Therapeutics The focus on RNA interference (RNAi) technologies is driving the development of miRNA-based drugs for treating diseases like cancer and genetic disorders.

Liquid Biopsies and miRNA Liquid biopsy technologies, which use miRNA as biomarkers, are revolutionizing non-invasive disease diagnostics, particularly in oncology.

Rising Collaborations Between Academia and Industry Academic institutions and biotech companies are forming partnerships to advance miRNA research and bring innovative products to market.

The Future of the MicroRNA Market

The global microRNA market holds immense potential, driven by its expanding applications across diagnostics and therapeutics. With increasing investments in research and the growing adoption of RNA-based technologies, the market is set to achieve remarkable growth in the coming years.Emerging regions, coupled with advancements in precision medicine and sustainable healthcare practices, will further drive innovation in this sector. Companies that prioritize R&D and focus on developing personalized solutions are well-positioned to lead the market in the future.

[industrynewsupdates]

Global Europe, Cis & Africa Spatial Transcriptomics Market: Insights and Market Forecast

The Europe, CIS & Africa spatial transcriptomics market was valued at approximately USD 93.9 million in 2023 and is expected to experience robust growth, with a projected compound annual growth rate (CAGR) of 15.57% from 2024 to 2030. Several key factors are contributing to this growth, including the increasing recognition of spatial omics analysis in cancer research, the introduction of fourth-generation sequencing technologies (such as in-situ sequencing), and a surge in funding and collaborative initiatives aimed at advancing spatial biology research.

A primary driver behind the market expansion is the rising prevalence of cancer. As cancer rates continue to climb, there is an increasing demand for more effective approaches to biomarker discovery, early detection, and precise diagnostics. These advancements are critical for better disease management and more targeted treatment options. Spatial omics analysis, particularly in the field of oncology, has shown considerable promise in addressing these needs. It offers a more nuanced understanding of tumor heterogeneity, supports the identification of potential biomarkers, and helps inform personalized treatment strategies that can be tailored to individual patients.

One of the major advantages of spatial omics technologies is their ability to map the spatial distribution of various cell types within a tumor. This feature is vital for studying the heterogeneity of tumors, which can significantly affect treatment outcomes. A relevant example of this is a study published in Nature in May 2024, where researchers employed both spatial and single-cell transcriptomics to explore the molecular interactions and tumor heterogeneity in colorectal cancer (CRC). By using these advanced techniques, the researchers were able to gain deeper insights into the underlying mechanisms driving CRC progression, showcasing the potential of spatial transcriptomics in improving our understanding of complex diseases like cancer.

Gather more insights about the market drivers, restrains and growth of the Europe, Cis & Africa Spatial Transcriptomics Market

Country Insights

Europe led the spatial transcriptomics market in 2023, commanding a dominant share of 94.57%. This dominance can be attributed to the region's well-established biotechnology research and development (R&D) sector, its growing emphasis on spatial biology, and the presence of leading industry players. Additionally, substantial investments and funding from both public and private entities have significantly contributed to advancing spatial transcriptomics research and facilitating the commercialization of spatial omics products, further driving market growth.

United Kingdom (UK):

The spatial transcriptomics market in the UK is anticipated to experience significant growth in the coming years. This is largely due to the continuous technological advancements in spatial biology, which are increasingly being applied across various fields such as oncology, neurology, and personalized medicine. A key example of the UK's role in fostering innovation is the 12th Annual Single Cell & Spatial Analysis UK Congress, part of Next Gen Omics 2024, scheduled for October 23-25, 2024, in London. This prominent event will bring together leading experts from around the world to discuss the latest developments, cutting-edge technologies, and future prospects of spatial biology, underscoring the UK's position as a hub for research and innovation in the field.

Germany:

Germany's spatial transcriptomics market is experiencing significant growth, particularly within the broader multi-omics field. The country benefits from active engagement by renowned academic institutions, leading biotechnology and pharmaceutical companies, and substantial government-backed research funding. For example, in early 2024, the European Molecular Biology Laboratory (EMBL) hosted a series of events and training courses, focusing on integrating and analyzing multiomics data, further enhancing the country's position in spatial transcriptomics and related fields.

France:

In France, the spatial transcriptomics market is also set to witness strong growth, driven by the increasing adoption of advanced genomic technologies and their expanding applications across diverse fields such as cancer research, drug discovery, and translational research. Moreover, the French government’s continued investment in genomic research initiatives is providing a solid foundation for the market’s development, fostering both innovation and collaboration in the space.

Commonwealth of Independent States (CIS) Market Trends

The CIS region, which includes countries such as Russia, Ukraine, Belarus, and Kazakhstan, is expected to see growth in the spatial transcriptomics market. This growth is largely fueled by an increased adoption of advanced genomics and transcriptomics technologies, a growing focus on spatial biology research, and rising demand for more detailed insights into cellular function and organization. These CIS countries are home to several well-established research institutions and academic centers with deep expertise in molecular biology and biotechnology, providing a strong foundation for growth in spatial transcriptomics research and applications.

Africa Spatial Transcriptomics Market Trends

South Africa is expected to experience significant growth in the spatial transcriptomics market, driven by an increased demand for improved diagnostic tools that support disease prevention and treatment. The country’s growing healthcare sector, combined with ongoing advancements in genomic technologies, creates a promising landscape for the adoption of spatial transcriptomics.

In contrast, the Nigerian market for spatial transcriptomics remains in its early stages. While there is potential for growth, the market faces challenges due to the high costs associated with specialized equipment and reagents. Additionally, the need for skilled labor to operate these advanced technologies represents another potential barrier to rapid market development. As such, significant investment in infrastructure, training, and research capacity will be necessary to accelerate market growth in Nigeria and other parts of West Africa.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global exosomes market size was estimated at USD 177.4 million in 2024 and is anticipated to grow at a CAGR of 28.73% from 2025 to 2030. 

• The global cell culture media storage containers market size was estimated at USD 2.11 billion in 2024 and is projected to witness a CAGR of 12.55% from 2025 to 2030. 

Key Europe, CIS & Africa Spatial Transcriptomics Company Insights

Several key players in the spatial transcriptomics market are actively pursuing strategies to strengthen their market presence and expand the reach of their products and services. These strategies primarily include expansion activities and strategic partnerships aimed at advancing research, increasing the commercialization of spatial omics products, and enhancing collaborations between academia and industry. Through these initiatives, companies are not only boosting their market footprint but are also contributing to the broader advancement of spatial biology and transcriptomics technologies.

Key Europe, CIS & Africa Spatial Transcriptomics Companies:

• Illumina, Inc.

• Bruker

• 10X Genomics

• EdenRoc Sciences (Cantata Bio, LLC)

• Shimadzu Corporation

• Waters Corporation

• Bio-Techne

• Vizgen Inc.

• Spatial Genomics

• Akoya Biosciences, Inc

Order a free sample PDF of the Europe, Cis & Africa Spatial Transcriptomics Market Intelligence Study, published by Grand View Research.

[farmacuticals]

Understanding the Ataxia Market: Emerging Treatments and Trends

Ataxia is a neurological disorder that affects coordination, movement, and balance. It results from damage to the cerebellum, the part of the brain responsible for coordinating voluntary movements. Ataxia can be caused by various factors, including genetic mutations, head injuries, stroke, alcohol abuse, and certain medications. The disorder is characterized by symptoms such as slurred speech, difficulty with balance, and uncoordinated movements, which can significantly impact a person's quality of life. The severity and progression of ataxia vary, with some forms being more degenerative than others.

In 2022, the ataxia market was projected to be worth 2.0 billion USD, according to MRFR analysis. By 2032, the ataxia market industry is projected to have grown from 2.1 billion USD in 2023 to 3.4 billion USD. During the projected period (2024-2032), the ataxia market's compound annual growth rate (CAGR) is anticipated to be approximately 5.48%.

Ataxia Size and Share

The ataxia market has been growing in recent years, driven by an increase in neurological research and advancements in diagnostic methods. The ataxia size is expanding as more cases are diagnosed due to better awareness and accessibility of healthcare services. The ataxia share in the neurological disorder market is influenced by both pharmaceutical developments and an increase in clinical trials focused on understanding the underlying causes and potential treatments for ataxia. The rising incidence of genetic disorders that contribute to ataxia cases is also a significant factor. As research continues to evolve, the ataxia share within the healthcare market is anticipated to grow further, underscoring the importance of continued investment and innovation in this area.

Ataxia Analysis

A thorough ataxia analysis reveals that the disorder is complex, with numerous subtypes and underlying genetic factors. The analysis of ataxia cases shows a diverse demographic, affecting individuals of various ages and backgrounds. Diagnostic advancements, such as genetic testing and neuroimaging, have improved the accuracy of ataxia analysis, allowing for earlier intervention and better management of symptoms. Research is also increasingly focusing on the molecular and genetic pathways that contribute to the disease, offering new insights into potential therapeutic targets. Furthermore, ataxia analysis emphasizes the need for comprehensive patient support, as managing symptoms often involves a multidisciplinary approach that includes physiotherapy, occupational therapy, and lifestyle modifications.

Ataxia Trends

Current ataxia trends indicate a rise in research focusing on gene therapy, stem cell therapy, and pharmacological interventions to slow disease progression. Emerging trends in the field also emphasize personalized treatment approaches, which cater to individual patients based on their genetic and environmental factors. Advances in neuroimaging and biomarkers are helping to refine diagnostic criteria and track disease progression, adding to the growing database of knowledge on ataxia. Additionally, there is an increasing trend towards community engagement and awareness initiatives that aim to support patients and their families while advocating for further research funding and policy support. These ataxia trends highlight a proactive approach towards improving patient outcomes and quality of life.

Reasons to Buy Ataxia Reports

Comprehensive Market Insights: Reports provide in-depth data on the ataxia size and ataxia share within the neurological disorders market, offering a comprehensive overview of industry growth, key players, and market dynamics.

Cutting-Edge Analysis: Buyers receive detailed ataxia analysis, covering current research, treatment options, and emerging therapies that are expected to shape the future of ataxia care.

Trend Forecasting: Reports offer insights into ataxia trends, allowing businesses and healthcare providers to stay ahead of industry shifts and leverage new opportunities in patient care.

Competitive Advantage: By accessing the latest developments and innovative treatment approaches, organizations can position themselves as leaders in the ataxia market.

Strategic Planning Support: Reports provide data-driven recommendations, enabling stakeholders to make informed decisions on investment, resource allocation, and R&D initiatives in ataxia.

Recent Developments in Ataxia Research

Recent developments in ataxia research have centered around gene therapy and drug repurposing efforts. Gene therapy, especially for hereditary ataxias, aims to replace or modify the affected genes to slow down or potentially halt disease progression. Additionally, researchers are repurposing drugs originally developed for other neurological disorders, which has shown promise in managing symptoms and improving patient quality of life. There have also been advancements in wearable technology to aid patients with movement and balance issues, and these devices may become integral to ataxia management in the future. With these developments, the outlook for ataxia treatment and quality of life improvements is steadily advancing.

Related reports:

hpv testing pap test market

infection surveillance solution market

iot medical device market

[amrutatbrc1]

Neurological Disorder Drugs Market 2024-2033 : Demand, Trend, Segmentation, Forecast, Overview And Top Companies 

The neurological disorder drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Neurological Disorder Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $79.67 billion in 2023 to $84.60 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $108.05 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

Order your report now for swift delivery @

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers -

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2021, according to a report published by the UK Parliament, a UK-based government body, the number of people waiting to begin neurology treatment increased to 140,482 in June 2021, up from 134,245 in May 2021. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs market.

Market Trends -

Major companies operating in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody used as a therapeutic drug in the treatment of multiple sclerosis (MS), a type of neurological disorder. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), based on over 10 years of clinical and real-world data. It is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the autoimmune attack on the central nervous system in multiple sclerosis (MS). Ocrevus is used to treat both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it the first drug approved for both forms of the disease. It is administered intravenously, typically every six months, and has shown efficacy in reducing disease activity and disability progression in clinical trials.

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Get an inside scoop of the neurological disorder drugs market, Request now for Sample Report @

Regional Insights -

North America was the largest region in the neurological disorder drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Table of Contents

1. Executive Summary

2. Neurological Disorder Drugs Market Report Structure

3. Neurological Disorder Drugs Market Trends And Strategies

4. Neurological Disorder Drugs Market – Macro Economic Scenario

5. Neurological Disorder Drugs Market Size And Growth

…..

27. Neurological Disorder Drugs Market Competitor Landscape And Company Profiles

28. Key Mergers And Acquisitions

29. Future Outlook and Potential Analysis

30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[harshnews]

Neurological Biomarkers Market Size, Share, Trends, Growth and Competitive Analysis

"Neurological Biomarkers Market – Industry Trends and Forecast to 2030

Global Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) – Industry Trends and Forecast to 2030.

Access Full 350 Pages PDF Report @

**Segments**

- **Product Type**: The market can be segmented based on the product type into neurogenomics, proteomics, metabolomics, and genomics. - **Application**: Segmentation by application includes diagnostics, personalized medicine, drug discovery, prognostics, and others. - **End-User**: The market can be categorized by end-users such as hospitals, research institutes, diagnostic laboratories, and others.

Neurological biomarkers play a crucial role in the early and accurate diagnosis of various neurological disorders. The market is segmented based on several key factors that impact the demand and growth of neurological biomarkers. Product type segmentation includes neurogenomics, proteomics, metabolomics, and genomics, each playing a unique role in identifying biomarkers associated with neurological conditions. Application-based segmentation covers diagnostics, personalized medicine, drug discovery, and prognostics, highlighting the diverse utility of neurological biomarkers across different medical settings. End-user segmentation includes hospitals, research institutes, diagnostic laboratories, and other healthcare facilities that utilize neurological biomarkers for improved patient care and disease management.

**Market Players**

- **Thermo Fisher Scientific Inc.**: Thermo Fisher Scientific Inc. is a prominent player offering a wide range of neurological biomarker solutions for research and clinical applications. - **Merck KGaA**: Merck KGaA is a key market player known for its innovative neurological biomarker products and services aimed at advancing neurology research. - **Abbott Laboratories**: Abbott Laboratories is recognized for its contributions to the neurological biomarkers market through the development of cutting-edge diagnostic tools. - **F. Hoffmann-La Roche Ltd**: F. Hoffmann-La Roche Ltd is a leading player offering comprehensive neurological biomarker solutions for precision medicine and drug development. - **QIAGEN**: QIAGEN is a significant player providing high-quality biomarker technologies and assays for neurological research and diagnostics.

These market players are at the forefront of driving innovation and advancements in the field of neurological biomarkersThermo Fisher Scientific Inc. holds a prominent position in the neurological biomarkers market, offering a diverse range of solutions tailored for both research and clinical applications. The company's extensive portfolio encompasses neurogenomics, proteomics, metabolomics, and genomics products that cater to the specific needs of studying neurological disorders. Thermo Fisher Scientific's commitment to innovation and quality has solidified its reputation as a trusted provider of neurological biomarker solutions. By staying at the forefront of technological advancements and scientific research, the company continues to drive progress in the field of neurology.

Merck KGaA is another key player that stands out in the neurological biomarkers market due to its focus on delivering innovative products and services designed to advance neurology research. The company's dedication to developing cutting-edge neurological biomarker solutions has positioned it as a significant contributor to the market's growth and development. Merck KGaA's strategic collaborations and investment in research and development have enabled it to introduce novel approaches and technologies that have the potential to revolutionize the way neurological disorders are diagnosed and treated.

Abbott Laboratories has made substantial contributions to the neurological biomarkers market by pioneering the development of state-of-the-art diagnostic tools that aid in the early detection and management of neurological conditions. The company's unwavering commitment to improving patient outcomes through the provision of reliable and accurate neurological biomarker solutions has earned it a strong reputation in the industry. Abbott Laboratories' focus on leveraging scientific expertise and technological innovation underscores its dedication to addressing unmet medical needs in the neurology space.

F. Hoffmann-La Roche Ltd has established itself as a leading player in the neurological biomarkers market by offering comprehensive solutions that support precision medicine and drug development in neurology. The company's commitment to advancing neurology through the development of innovative biomarker technologies underscores its dedication to addressing the evolving needs of healthcare providers and patients alike. F. Hoffmann-La Roche Ltd's holistic approach to neurological biomarkers encompasses a wide range of applications, from diagnostics to ther**Global Neurological Biomarkers Market Analysis**

- The global neurological biomarkers market is witnessing significant growth attributed to rising prevalence of neurological disorders and increased investment in neuroscience research. - Genomics biomarkers segment is expected to dominate the market, driven by advancements in genomics technology and the ability to identify genetic markers associated with neurological conditions. - Alzheimer's Disease indication holds a substantial share due to the high prevalence of the disease globally and the urgent need for effective diagnostic and treatment solutions. - Imaging techniques such as functional magnetic resonance imaging and positron emission tomography are gaining traction for their ability to provide detailed insights into neurological conditions and facilitate personalized treatment approaches. - Pharmaceutical and biotechnology companies are the key end-users of neurological biomarkers, leveraging these tools for drug discovery, clinical trials, and precision medicine initiatives.

The global neurological biomarkers market is poised for substantial growth in the coming years, fueled by technological advancements, increasing disease burden, and growing focus on personalized medicine in neurology. Genomics biomarkers are anticipated to lead the market, supported by their ability to provide valuable genetic insights into neurological disorders and aid in the development of targeted therapies. The emergence of advanced imaging techniques like functional MRI and PET imaging is revolutionizing neurology by enabling precise diagnosis and monitoring of neurological conditions.

Alzheimer's Disease, a prevalent neurological disorder, is expected to drive significant demand for biomarkers, given the urgent need for early detection and disease management strategies. Pharmaceutical and biotechnology companies are investing heavily in neurological biomarkers for drug

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Neurological Biomarkers Market Landscape

Part 04: Global Neurological Biomarkers Market Sizing

Part 05: Global Neurological Biomarkers Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Neurological Biomarkers Key Benefits over Global Competitors:

The report provides a qualitative and quantitative analysis of the Neurological Biomarkers Market trends, forecasts, and market size to determine new opportunities.

Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Top impacting factors & major investment pockets are highlighted in the research.

The major countries in each region are analyzed and their revenue contribution is mentioned.

The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Browse Trending Reports:

Mhealth Solutions Market Telecom Cloud Billing Market Industrial Cooking Fire Protection Systems Market Food Manufacturing Market Natural Surfactant Market Industrial Networking Solutions Market Facility Management Market Cathode Materials Market High Purity Gases Market Cassava Starch Market Embedded Connectivity Solutions Market Central Fill Pharmacy Automation Market Rfid In Healthcare Market Virtual Pipeline Systems Market Fiberoptic Phototherapy Equipment Market Suture Passer Market Baby Apparel Market Peanut Allergy Treatment Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[tamanna31]

Clinical Trial Imaging 2023 Industry Report Potential Growth, Share, Demand And Forecast to 2030

Clinical Trial Imaging Industry Overview

The global clinical trial imaging market size was estimated at USD 1.14 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.60% from 2024 to 2030. The market growth is anticipated to be fueled by the growing biotechnology and pharmaceutical sectors, coupled with rising investments in research and development for the creation of new drugs aimed at treating various diseases. Medical imaging plays a pivotal role in advancing the development of innovative life science products.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Imaging Market

Despite the ever-changing nature of the medical imaging industry, the biotechnology and pharmaceutical industries are showing sustained growth. This is primarily due to the increased investment in medical imaging companies, as well as the occurrence of mergers and acquisitions that involve the incorporation of cutting-edge imaging technologies to facilitate clinical trials for medical devices.

Advancements in technology are bringing substantial improvements to the collection, evaluation, and submission of clinical trial imaging data. Technology-enabled imaging, especially image analysis software, provides various benefits to clinical studies, such as consistency, data accuracy, adaptability, and compliance. For instance, image analysis software is used to direct and manage a reader by analyzing imaging time points. In addition, the increased use of imaging technology, along with the enhanced power of computing, is expected to drive the usage of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) protocol has come up with standardized methods and imaging procedures with uniform procedures to be implemented for attaining statistical and precise endpoints in clinical trials.

The Covid-19 pandemic has adversely impacted the healthcare system in most countries, leading to a disruption in medical studies, and research activities, and reduced sponsorship for research involving clinical trials. The pandemic hampered the clinical trial timeline as numerous ongoing studies were delayed and planned studies were cancelled. Unfavorable changes in regulations and guidelines, supply chain disruption, recruitment challenges for clinical trials, fear of viral spread, and shutting down of most manufacturers during lockdown have adversely impacted the market. However, introducing virtual imaging trials during the COVID-19 pandemic is expected to open new avenues for adopting these devices. The development of advanced computational models helps better assess CT and radiography images, which are expected to help in the early diagnosis of COVID-19 patients. The market has witnessed a bounce back by 2022 Q2 due to increased R&D activities and improvement in supply and distribution channels.

Many patents have been filed in the realm of enhancing image evaluation and capturing. In addition, imaging core lab provider’s offer patented technologies that are anticipated to assist pharmaceutical companies in reducing their development timelines. As an example, IXICO provides a diagnostic tool called Assessa, which enhances decision-making in clinical trials for conditions related to memory, including schizophrenia, Parkinson's, and Alzheimer's disease, as well as neurological disorders such as dementia and cognitive impairment. However, the high cost of machinery and their installation, and the enormous cost of clinical trials may limit the market growth during the forecast periods. Advancements in technology are bringing substantial improvements to the collection, evaluation, and submit clinical trial imaging data. Technology-enabled imaging especially image analysis software provides various benefits to clinical studies such as consistency, data accuracy, adaptability as well as compliance. For instance, image analysis software is used to direct and manage a reader via analysis of imaging time points.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global mobile stroke unit market size was valued at USD 35.80 million in 2023 and is projected to grow at a CAGR of 5.2% from 2024 to 2030. Rising incidence of strokes increased focus on early treatment of stroke patients are driving the demand for efficient and timely stroke care services.

• The global brain tumor diagnosis and therapeutics market size was valued at USD 3.11 billion in 2023 and is projected to grow at a CAGR of 7.1% from 2024 to 2030. The growing launches of brain tumor therapeutics products and the rise in cancer awareness for brain tumor medications drive the market over the forecast period.

Clinical Trial Imaging Market Segmentation

Grand View Research has segmented the clinical trial imaging market on the basis of on service, modality, application, end-use and region:

Clinical Trial Imaging Service Outlook (Revenue, USD Million, 2018 - 2030) • Clinical Trial Design and Consultation Services • Reading and Analytical Services • Operational Imaging Services • System and Technology Support Services • Project and Data Management

Clinical Trial Imaging Modality Outlook (Revenue, USD Million, 2018 - 2030) • Computed Tomography • Magnetic Resonance Imaging • X-Ray • Ultrasound • Optical Coherence Tomography (OCT) • Others

Clinical Trial Imaging Application Outlook (Revenue, USD Million, 2018 - 2030) • NASH • CKD • Diabetes • Cardiovascular Diseases • Ophthalmology • Musculoskeletal • Oncology • Gastroenterology • Pediatrics • Others

Clinical Trial Imaging End-use Outlook (Revenue, USD Million, 2018 - 2030) • Biotechnology and Pharmaceutical companies • Medical Devices Manufacturers • Academic and Government Research Institutes • Contract Research Organizations (CROs) • Others

Clinical Trial Imaging Regional Outlook (Revenue, USD Million, 2018 - 2030) • North America o U.S. o Canada • Europe o UK o Germany o France o Italy o Spain o Denmark o Sweden o Norway • Asia Pacific o India o China o Japan o Australia o Thailand o South Korea • Latin America o Brazil o Mexico o Argentina • Middle East & Africa o South Africa o Saudi Arabia o UAE o Kuwait

Order a free sample PDF of the Clinical Trial Imaging Market Intelligence Study, published by Grand View Research.

Key Companies profiled: • IXICO plc • Navitas Life Sciences • Resonance Health • ProScan Imaging • Radiant Sage LLC • Medpace • Biomedical Systems Corp • Cardiovascular Imaging Technologies • Intrinsic Imaging • BioTelemetry

Recent Developments

• In March 2023, Clario launched a cloud-based image viewer specifically for clinical trials. This innovation aims to streamline medical image analysis and improve its accessibility within the clinical research context

• In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized solutions for cardiac health, which involve analyzing and devising treatment strategies for cardiovascular issues. The partnership is expected to leverage Cleerly's AI-powered platform to examine coronary CT angiography (CCTA) images

[windyjohn1]

Global Biomarkers Market report

The Global Biomarkers Market report focuses on various aspects of the market, Key Growth Drivers Include Rising Demand for Personalized Medicine, Drug Discovery & Development, and Diagnostics | By Type, Disease, and Application. The market is expected to reach USD 283.5 million by 2033. Growth: The market is projected to grow from USD 84.3 million in 2023 to USD 283.5 million by 2033, with a CAGR of 14.2% over the period. Key characteristics driving the market include the increasing demand for personalized medicine, advancements in drug discovery and development, and the growing use of biomarkers in diagnostics. North America held the largest market share in 2023, driven by advanced healthcare infrastructure, high adoption of personalized medicine, and significant investments in research and development.

The Biomarkers market encompasses the research, development, and application of biological markers used to measure and evaluate biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are crucial in personalized medicine, diagnostics, and drug discovery.

Key Market Drivers

Rising Demand for Personalized Medicine: Personalized medicine relies heavily on biomarkers to tailor treatments to individual patients, driving the market growth.

Advancements in Drug Discovery and Development: Biomarkers are essential in identifying potential drug targets and monitoring therapeutic responses, significantly contributing to market expansion.

Increasing Prevalence of Chronic Diseases: The rising incidence of diseases such as cancer, cardiovascular diseases, and neurological disorders necessitates the use of biomarkers for early diagnosis and treatment.

Technological Advancements in Biomarker Discovery: Innovations in technologies such as genomics, proteomics, and bioinformatics are enhancing biomarker discovery and validation processes.

Growing Use of Biomarkers in Diagnostics: Biomarkers play a crucial role in early disease detection, prognosis, and monitoring, boosting their adoption in diagnostic applications.

Get more information on “ Global Biomarkers Market Report ” by requesting FREE Sample Copy at 

https://www.eternalmarkets.com/report/biomarkers-market-2024-global-dynamics-trends-forecast/#tab-request-sample

Restraining Factors

High Costs Associated with Biomarker Development: The development and validation of biomarkers are expensive and time-consuming, which can limit market growth.

Regulatory Challenges: Stringent regulatory requirements and lengthy approval processes can hinder the introduction of new biomarkers.

Limited Availability of Qualified Biomarkers: The identification and validation of reliable biomarkers remain challenging, restricting their widespread application.

Ethical and Privacy Concerns: The use of biomarkers, particularly in genetic testing, raises ethical and privacy issues, potentially affecting their acceptance and adoption.

Technical Challenges in Biomarker Validation: Ensuring the accuracy, specificity, and reproducibility of biomarkers is technically challenging, posing a barrier to market growth.

Future Outlook

Expansion of Biomarker Applications in Emerging Fields: The application of biomarkers is expected to expand into new areas such as neurodegenerative diseases, immunological disorders, and metabolic diseases.

Development of Multi-Omics Biomarkers: Combining genomics, proteomics, and metabolomics to develop multi-omics biomarkers could provide comprehensive insights into disease mechanisms and improve diagnostic accuracy.

Increased Focus on Companion Diagnostics: The growing trend of using biomarkers in companion diagnostics to guide targeted therapies will drive market growth.

Collaborations and Partnerships: Increased collaborations between pharmaceutical companies, research institutions, and diagnostic companies will enhance biomarker discovery and development.

Regulatory Support and Funding: Government initiatives and funding for biomarker research and development will continue to propel market growth.

Key Players

F. Hoffmann-La Roche AG

Epigenomics AG

Abbott

Thermo Fisher Scientific Inc

General Electric

Eurofins Scientific

Johnson & Johnson Services, Inc.

QIAGEN

Bio-Rad Laboratories, Inc.

Siemens Healthineers AG

Merck KGaA

PerkinElmer Inc.

Agilent Technologies, Inc.

Other Market Leaders In The Business

Inquire Before Buying at 

https://www.eternalmarkets.com/report/biomarkers-market-2024-global-dynamics-trends-forecast/#tab-inquire-before-buying

Recent Developments

2023: F. Hoffmann-La Roche AG launched a new biomarker-based diagnostic tool for early cancer detection.

2022: Abbott acquired Epigenomics AG to enhance its biomarker discovery capabilities.

2022: Thermo Fisher Scientific Inc. partnered with QIAGEN to develop advanced biomarker testing solutions.

2021: Siemens Healthineers AG introduced a new biomarker assay for cardiovascular disease diagnostics.

Market Segmentation

By Type: Validation, Efficacy, Safety

By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Others

By Application       : Personalized Medicines, Drug Discovery & Development, Diagnostics, Others

By Geography:

Asia-Pacific: China, Japan, India, Rest of APAC (RoAPAC)

North America: U.S., Canada

Europe: Germany, U.K., France, Italy, Spain, Rest of Europe (RoE)

South America: Brazil, Argentina, Rest of South America

Middle East & Africa: GCC, Israel, South Africa, Rest of MEA

Regional Insights

Europe: Europe is expected to show substantial growth due to strong government support for biomarker research, well-established pharmaceutical industry, and increasing focus on personalized medicine.

Asia-Pacific: The Asia-Pacific region is projected to witness the highest growth rate, fueled by rising healthcare expenditure, growing awareness about personalized medicine, and increasing prevalence of chronic diseases.

Final Insights

The Global Biomarkers Market is poised for substantial growth over the next decade, driven by advancements in personalized medicine, drug discovery and development, and diagnostics. The market is expected to reach USD 283.5 million by 2033, with a CAGR of 14.2%. Key drivers include rising demand for personalized medicine, technological advancements, and increasing prevalence of chronic diseases. However, challenges such as high costs, regulatory hurdles, and technical validation issues need to be addressed to fully realize the market’s potential.

About Us:

Eternal Markets offers premium dynamic measurable looking over, statistical surveying reports, investigation and figure information for enterprises and governments around the world.

Eternal Markets see how fundamental measurable looking over data is for your association or affiliation. In this manner, we have related with the top distributors and research firms all had practical experience in explicit areas, guaranteeing you will get the most dependable and exceptional research information accessible. We additionally give COTS (Commercial off the Shelf) business division reports as custom investigation concurring your specific needs.

Contact Us:

Eternal Markets

2985, Cedar Brook drive, Decatur GA 30033, USA

T: +1-860-419-5851

For Sales Enquiries: sales@eternalmarkets.com

Website: https://www.eternalmarkets.com

[poonamcmi]

Neurodiagnostics Market Estimated to Witness High Growth Owing to Growing Geriatric Population

​The neurodiagnostics market plays a crucial role in neurological disease diagnosis and treatment monitoring. Neurological disorders such as epilepsy, Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and other neurological conditions are becoming increasingly prevalent. Neurodiagnostics help detect neurological abnormalities through neurological imaging such as MRI, EEG, and diagnostic tests. The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics.

The Global Neurodiagnostics Market is estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.

Key Takeaways Key players operating in the neurodiagnostics are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.

The Neurodiagnostics Market Trends  include increasing investments in R&D for biomarker-based disease diagnosis and neuroimaging. The global expansion of key players through mergers and acquisitions will further aid market growth.

The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics. Furthermore, increasing investments in R&D by key players for developing advanced diagnostic systems will boost the neurodiagnostics market over the forecast period.

Market drivers The growing geriatric population is the major driver propelling the Neurodiagnostics Market Size And Trends As per the United Nations, people aged over 60 years are projected to outnumber children under 10 years by 2050. Elderly people are more vulnerable to neurological disorders like Alzheimer's and Parkinson's disease. This will augment the demand for neurodiagnostics for early disease diagnosis and treatment monitoring. Increasing awareness about brain health and availability of reimbursement policies for neurodiagnostic tests will also boost market revenues significantly over the forecast period.

PEST Analysis Political: Regulations related to medical devices and neurological disorder treatments have an impact. Reimbursement policies by governments and insurance agencies also affect market growth. Economic: The growing insurance coverage levels and disposable incomes have boosted healthcare spending including on neurodiagnostics. Higher investments in clinical trials and R&D remain crucial. Social: Rising prevalence of neurological disorders like Alzheimers, Parkinsons, epilepsy, and stroke is a key driver. Growing awareness encourages early diagnosis through imaging techniques. Technological: Advancements in imaging modalities like MRI, CT, PET, EEG, and newer technologies like digital EEG and MEG expands diagnosis capabilities. Portable and wearable devices improve accessibility.

Geographical Regions with High Market Concentration North America accounts for the largest share in the neurodiagnostics market in terms of value, owing to the presence of major players, high healthcare expenditure, and rising neurological disorders. The United States holds a significant share in the regional market.

Fastest Growing Regional Market The Asia Pacific region is expected to witness the highest growth in the neurodiagnostics market during the forecast period. This is attributed to factors such as growing healthcare expenditure, increasing healthcare infrastructure development, and rising geriatric population in the region suffering from neurological conditions. Rapidly developing countries like China and India with huge patient pools offer high growth potential. Get More Insights On, Neurodiagnostics Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)